diisopropyl 1,3-dithiol-2-ylidenemalonate (malotilate)

08/01/2003 - "Three hundred and seventy patients with alcoholic liver disease were studied in a trial of malotilate with a median follow-up period of 470 days; 75 patients died; 336 patients had a liver biopsy on entry. "
07/21/1997 - "Three hundred and thirty-seven patients with alcoholic liver disease were studied in a randomised placebo-controlled trial of malotilate with a mean follow-up period of 569 days (range: 7-1544). "
04/01/1994 - "Four hundred and seven patients with alcoholic liver diseases, from seven European liver units, entered a randomized placebo-controlled, double-blind trial: 140 patients received malotilate 1500 mg/day, 133 patients received 750 mg/day, and 134 patients received placebo. "
04/01/1994 - "The aim of this study was to examine the effect of malotilate on survival in patients with alcoholic liver disease and to determine prognostic variables for survival. "
05/01/1989 - "However, the effects of malotilate on alcoholic liver disease are not well known. "

06/01/1992 - "Precise mechanism of the inhibitory effect of malotilate on liver cirrhosis is not elucidated, but this substance is clearly effective for preventing liver cell damage and/or liver cirrhosis caused by CCl4."
12/01/1988 - "These effects of malotilate improved the prognosis of liver cirrhosis."
06/01/1992 - "Previously established liver cirrhosis, however, could not be normalized by malotilate treatment. "
06/01/1992 - "During the six to ten weeks of the experimental period, liver cirrhosis was perfectly inhibited by malotilate. "
06/01/1992 - "Malotilate completely inhibits CCl4-induced liver cirrhosis in rats: biochemical and morphological analysis."

01/01/1987 - "Malotilate: the new hope for a clinically effective agent for the treatment of liver disease."
12/01/1988 - "These results indicate that the effects of malotilate on chronic liver diseases are not simply biocosmetic, but rather are related to an improvement in the basal changes of the liver, including a decrease in the fibrogenetic stimulus. "
05/01/1996 - "Three hundred thirty-seven patients with alcohol-induced liver disease were studied in a randomized placebo-controlled trial of malotilate with a mean follow-up period of 569 days (range, 7-1,544). "
09/01/1987 - "Malotilate is a new drug suggested for use in chronic liver diseases. "
01/01/1986 - "Treatment of liver disease with malotilate. "

02/01/1993 - "One hundred and one patients were included in a double-blind controlled trial to determine whether malotilate (diisopropyl 1,3-dithiol-2-ylidene malonate) is therapeutically effective in primary biliary cirrhosis. "
02/01/1993 - "The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. "
02/01/1993 - "We conclude that malotilate has an immune-modulating, anti-inflammatory but not anti-fibrotic effect in primary biliary cirrhosis. "
02/01/1993 - "The clinical relevance of the observed benefits, however, appears too slight to recommend malotilate as single drug therapy in primary biliary cirrhosis."

08/01/1986 - "Protective effect of malotilate on the liver injuries induced by several hepatotoxins was studied in mice and rats. "
04/01/1996 - "It is concluded from these results that malotilate seems to be a promising agent for topical wound therapy."
04/01/1996 - "The rapid decrease in the square measure of wound areas and the improvement in the histological evaluation clarified that 0.3% and 1% cream preparations of malotilate were obviously effective in accelerating spontaneous healing in the normal rats. "
04/01/1996 - "The wound healing effect of malotilate (CAS 59937-28-9, NKK-105) was investigated by using an excisional skin-wound model produced on the back of normal and healing-impaired (induced by prednisolone pretreatment) rats. "
06/01/1998 - "Furthermore, malotilate, which is now under development as an agent for wound therapy, facilitated the migratory response of NHDF with increased collagenase secretion in this wound model, suggesting that the wound healing effect of malotilate is in part attributable to stimulated migration of fibroblasts to wounded areas subsequent to extracellular matrix-degradation."